Cargando…
Generics versus brand-named drugs for glaucoma: the debate continues
There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Romanian Society of Ophthalmology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739547/ https://www.ncbi.nlm.nih.gov/pubmed/33367157 |
_version_ | 1783623343952363520 |
---|---|
author | Bhartiya, Shibal Dhingra, Deepika |
author_facet | Bhartiya, Shibal Dhingra, Deepika |
author_sort | Bhartiya, Shibal |
collection | PubMed |
description | There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios. |
format | Online Article Text |
id | pubmed-7739547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Romanian Society of Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-77395472020-12-22 Generics versus brand-named drugs for glaucoma: the debate continues Bhartiya, Shibal Dhingra, Deepika Rom J Ophthalmol Reviews There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios. Romanian Society of Ophthalmology 2020 /pmc/articles/PMC7739547/ /pubmed/33367157 Text en ©Romanian Society of Ophthalmology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Bhartiya, Shibal Dhingra, Deepika Generics versus brand-named drugs for glaucoma: the debate continues |
title | Generics versus brand-named drugs for glaucoma: the debate continues
|
title_full | Generics versus brand-named drugs for glaucoma: the debate continues
|
title_fullStr | Generics versus brand-named drugs for glaucoma: the debate continues
|
title_full_unstemmed | Generics versus brand-named drugs for glaucoma: the debate continues
|
title_short | Generics versus brand-named drugs for glaucoma: the debate continues
|
title_sort | generics versus brand-named drugs for glaucoma: the debate continues |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739547/ https://www.ncbi.nlm.nih.gov/pubmed/33367157 |
work_keys_str_mv | AT bhartiyashibal genericsversusbrandnameddrugsforglaucomathedebatecontinues AT dhingradeepika genericsversusbrandnameddrugsforglaucomathedebatecontinues |